Replies to post #2971 on Insmed Inc (INSM)

[rod5247]

Looking at Herceptin in comparison with INSM-18, they appear to block the same receptor, (Her2/neu) but INSM-18 inhibits what Herceptin plus BP3 inhibits. "INSM-18, a small molecule tyrosine kinase inhibitor, has demonstrated selective inhibition of the insulin-like growth factor-I receptor (IGF-I) and human epidermal growth factor receptor (Her2/neu)." Since I don't claim to understand all of the scientific data, could this be a valid assumption or could INSM-18 + BP3 be a viable compound?